Mizuho raises Ardent Health stock price target to $21 on execution

Mizuho raised its price target on Ardent Health Partners (NYSE:ARDT) to $21 from $13, citing improved execution and higher earnings visibility. The stock is up 103% YTD. Ardent reported Q3 2026 adjusted earnings of $0.31 per share, beating estimates, and raised its adjusted EBITDA guidance to $500M-$535M. The company operates hospitals and healthcare facilities in the U.S.

Original reporting
Published Nov 11, 2026, 11:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 11:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ARDT
Bullish
high confidence
Mentioned
$ARDT
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ARDTBullishMed
01

Why it matters

The upgrade may trigger short covering and new buying, especially after after-hours price jump.

02

Market read

Analyst target raise provides a fresh catalyst for ARDT, potentially driving short-term price appreciation.

03

What to watch

Potential regulatory or payer pressure not addressed in the note.

Relevance 6/10Novelty 6/10Timing: pre-market today

Background

Ardent Health Partners operates hospitals across the US; the price target lift follows Q3 2026 performance and updated EBITDA forecasts.

Company-level read

Ticker impact

$ARDTBullishHigh confidence
Context

Mizuho raised its price target on Ardent Health Partners to $21 from $13, citing improved execution and higher EBITDA guidance.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

Target increase of 62% reflects stronger earnings visibility and cost savings, which can attract buying.

Market effects

May lift sentiment for other hospital operators as execution improvements are highlighted.

US healthcare sector could see modest gains.

Limited to US-listed healthcare stocks.

Counterpoint

Target raise could be premature if cost savings are not sustainable.

Key entities

  • Mizuho

    Equity research firm raising target.

  • Ardent Health Partners

    Hospital operator receiving upgraded target.

Related articles

$ARDTMed

BofA raises Ardent Health stock price target on acquisition upside

BofA Securities raised its price target on Ardent Health Partners (ARDT) to $14 from $12, citing the company's acquisition of Boone Health. The stock trades at $17.68, near its 52-week high. BofA expects the deal to add $5M-$10M in EBITDA in the first year, growing to $30M-$40M by the third year. Ardent reported Q3 2026 earnings of $0.31 per share, beating estimates. Mizuho also raised its target to $21, maintaining an Outperform rating.

$ARDTMed

What Ardent Health (ARDT) Said on Its Q3 Earnings Call

Ardent Health (ARDT) reported Q3 earnings, highlighting a 9% increase in urgent care visits and a 400 basis point decline in physician referral leakage. Labor costs fell 4.3% YoY, and the company plans to sell a Kansas hospital for 11x EBITDA. Ardent generated $122M in Q3 operating cash flow and lowered its 2026 capital expenditure guidance. The company remains 85% contracted for 2027 and 75% for 2028, with negotiations described as contentious.

$ARDTHighAI 8/10

Ardent Health (ARDT) Q3 2026 Earnings Call Transcript

Ardent Health (ARDT) reported Q3 2026 adjusted EBITDA of $138M, up 1.5% from prior guidance. Revenue was $1.62B, with adjusted admissions up 2.9%. The company plans to divest a Kansas hospital at 11x EBITDA, enhancing margins by 40bps. Ardent's IMPACT program aims for $70M in savings this year, and it raised its EBITDA guidance midpoint by 1.5%.